Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and clinical activity of maintenance
olaparib and pembrolizumab following multi-agent, low dose chemotherapy with gemcitabine,
nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with untreated
metastatic pancreatic ductal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins